

BRIAN SANDOVAL  
Governor



RICHARD WHITLEY, MS  
Director

MARTA JENSEN  
Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
DIVISION OF HEALTH CARE FINANCING AND POLICY  
1100 East William Street, Suite 101  
Carson City, Nevada 89701  
Telephone (775) 684-3676 • Fax (775) 687-3893  
<http://dhcfp.nv.gov>

## NOTICE OF PUBLIC MEETING – PHARMACY AND THERAPEUTICS COMMITTEE

### REVISED AGENDA

**Date of Publication:** February 22, 2018  
**Date of Revision:** March 15, 2018

**Date and Time of Meeting:** Thursday, March 22, 2018 at 1:00 PM

**Name of Organization:** The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)

**Place of Meeting:**

**North Nevada Location:**  
Legislative Council Bureau  
401 S. Carson Street, Suite 2134  
Carson City, Nevada 89701

**South Nevada Location:**  
Grant Sawyer Office Building  
555 E. Washington Avenue, Suite 4406 4412  
Las Vegas, Nevada 89101

**Please check with staff to verify room location**

**Teleconference:** (775) 687-0999

**Access Code:** 43722

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Colleen McLachlan at: (775) 684-3722 or email [cmclach@dhcfp.nv.gov](mailto:cmclach@dhcfp.nv.gov) in advance, but no later than two working days prior to the meeting so that arrangements may be conveniently made.

## AGENDA

1. **Call to Order and Roll Call**
2. **Public Comment**
3. **Administrative**
  - a. **For Possible Action:** Review and Approve Meeting Minutes from December 7, 2017
  - b. Status Update by the DHCFP
    1. Public Comment
4. **Proposed New Drug Classes**
  - a. Monoclonal Antibodies for the Treatment of Respiratory Conditions
    1. Public Comment
    2. Drug Class Review Presentation – OptumRx
    3. **For Possible Action:** Committee Discussion and Action
      - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
      - b. Identify Exclusions/Exceptions for Certain Patient Groups
    4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the DHCFP
    5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
5. **Established Drug Classes**
  - a. Analgesics – Opiate Agonists – Abuse Deterrent
    1. Public Comment
    2. Drug Class Review Presentation – OptumRx
    3. **For Possible Action:** Committee Discussion and Action
      - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
      - b. Identify Exclusions/Exceptions for Certain Patient Groups
    4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
    5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
  - b. Cardiovascular Agents – Antihypertensive Agents – Direct Renin Inhibitors
    1. Public Comment

2. Drug Class Review Presentation – OptumRx
3. **For Possible Action:** Committee Discussion and Action
  - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
  - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

**6. Established Drug Classes Being Reviewed Due to the Release of New Drugs**

- a. Analgesics – Opiate Agonists
  1. Public Comment
  2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- b. Cardiovascular Agents – Antilipemics – HMG-CoA Reductase Inhibitors (Statins)
  1. Public Comment
  2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- c. Hormones and Hormone Modifiers – Antidiabetic Agents – Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combination
  1. Public Comment
  2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups

4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- d. Respiratory Agents – Respiratory Anti-inflammatory Agents – Nasal Corticosteroids
1. Public Comment
  2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- e. Respiratory Agents – Respiratory Anti-inflammatory – Agents Respiratory Corticosteroids
1. Public Comment
  2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- f. Respiratory Agents – Respiratory Antimuscarinic Combinations.
1. Public Comment
  2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- g. Cardiovascular Agents – Antilipemics – Omega-3 Fatty Acids
1. Public Comment

2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
7. **Report by OptumRx on New Drugs to Market, New Generic Drugs to Market and New Line Extensions**
8. **Closing Discussion**
- a. Public comments on any subject
  - b. Date and location of the next meeting
  - c. Adjournment

**PLEASE NOTE:** Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to five minutes.

This notice and agenda have been posted at <http://dhcftp.nv.gov/> and [notice.nv.gov/](http://notice.nv.gov/).

---

Notice of this meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP Web site <http://dhcftp.nv.gov/>; Carson City Central office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the following locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a draft copy of the changes will be mailed to you. Requests and/or written comments on the proposed changes may be sent to the Colleen McLachlan at the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, NV 89701.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.